Milsaperidone (VHX-896) vs Risperidone (Risperdal)

Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.

Schizophrenia

Shared mechanism: Dopamine D2 and serotonin 5-HT2A receptors (antagonist) · full Schizophrenia pipeline

Milsaperidone (VHX-896)

Marketed by Vanda Pharmaceuticals

Approved in Schizophreniasmall molecule
Weak signal

NCT06494397 · Phase 1 · completed

Every participant in this trial received both VHX-896 and iloperidone, just in a different order, so there is no separate group that shows what happens without VHX-896, and nobody was blinded to which drug was being given at each stage. The trial measured drug levels in the blood to compare the two products, not any change in psychiatric symptoms, and results have not been posted yet.

No aligned efficacy figure on record for this race.

Risperidone (Risperdal)

Marketed by Johnson & Johnson

Approved in Schizophreniasmall molecule
not yet graded

No graded featured trial for this indication yet; the grade above reflects that absence, not a judgment.

Next expected readout: September 2027 · NCT04478838 (registry estimate)

No aligned efficacy figure on record for this race.

Results for Schizophrenia

Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.

Key endpointMilsaperidone (VHX-896)Risperidone (Risperdal)
PANSS total, change—Not reported-16.5 vs -9.2−7.2 vs placebo120 mg · wk 8 · n 114NCT02109562
1 other result
  • -15.4 vs -9.2 90 mg · wk 8 · n 111 · Phase 3 · primary NCT02109562
CGI-S, change—Not reported-0.9 vs -0.5−0.4 vs placebo120 mg · wk 8 · n 114NCT02109562
1 other result
  • -0.9 vs -0.5 90 mg · wk 8 · n 111 · Phase 3 · secondary NCT02109562
PANSS response—Not reported—Not posted · NCT00297388
PSP, change—Not reported—Not posted · NCT00297388
Relapse (% of patients)—Not reported—Not posted · NCT00297388

PANSS total, change

Milsaperidone (VHX-896)
—Not reported
Risperidone (Risperdal)
-16.5 vs -9.2−7.2 vs placebo120 mg · wk 8 · n 114NCT02109562
1 other result
  • -15.4 vs -9.2 90 mg · wk 8 · n 111 · Phase 3 · primary NCT02109562

CGI-S, change

Milsaperidone (VHX-896)
—Not reported
Risperidone (Risperdal)
-0.9 vs -0.5−0.4 vs placebo120 mg · wk 8 · n 114NCT02109562
1 other result
  • -0.9 vs -0.5 90 mg · wk 8 · n 111 · Phase 3 · secondary NCT02109562

PANSS response

Milsaperidone (VHX-896)
—Not reported
Risperidone (Risperdal)
—Not posted · NCT00297388

PSP, change

Milsaperidone (VHX-896)
—Not reported
Risperidone (Risperdal)
—Not posted · NCT00297388

Relapse (% of patients)

Milsaperidone (VHX-896)
—Not reported
Risperidone (Risperdal)
—Not posted · NCT00297388
  1. Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
  2. An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.

Milsaperidone (VHX-896): no structured comparison results are available for Schizophrenia.

Only safety results can currently be compared in this indication. Reviewed efficacy summaries, where available, are listed separately.

safety

Coverage. Milsaperidone (VHX-896): 0 of 4 rows · Risperidone (Risperdal): 4 of 4 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.

Reported metricRisperidone (Risperdal)
Dropout rate
78.3%180 mg subcutaneousa
NCT03978832 · Phase 4 · registry result, not featured evidence
show 22 more results
5.9%CT - Oral Ris
NCT00333177 · Phase 4 · registry result, not featured evidence
0%CT - RLAI
NCT00333177 · Phase 4 · registry result, not featured evidence
14.3%HBT - Oral Ris
NCT00333177 · Phase 4 · registry result, not featured evidence
5.9%HBT - RLAI
NCT00333177 · Phase 4 · registry result, not featured evidence
0%
NCT01050582 · Phase 4 · registry result, not featured evidence
17.5%
NCT01855074 · Phase 4 · registry result, not featured evidence
29.6%
NCT00299702 · Phase 4 · registry result, not featured evidence
0%PALI ER Delayed Initiation
NCT00535132 · Phase 4 · registry result, not featured evidence
0%PALI ER Immediate Initiation
NCT00535132 · Phase 4 · registry result, not featured evidence
16.7%
NCT00056498 · Phase 4 · registry result, not featured evidence
28.6%120 mg
NCT02109562 · Phase 3 · registry result, not featured evidence
22.4%90 mg
NCT02109562 · Phase 3 · registry result, not featured evidence
—4 mg
NCT04567524 · Phase 2 · registry result, not featured evidence
25%4 mg
NCT04567524 · Phase 2 · registry result, not featured evidence
—2 mg
NCT04567524 · Phase 2 · registry result, not featured evidence
0%2 mg
NCT04567524 · Phase 2 · registry result, not featured evidence
40%120 mg
NCT01677377 · Phase 2 · registry result, not featured evidence
6.7%90 mg
NCT01677377 · Phase 2 · registry result, not featured evidence
6.7%60 mg
NCT01677377 · Phase 2 · registry result, not featured evidence
29.4%DLP-114 Alpha-4 (6-months)
NCT04418466 · Phase 1/2 · registry result, not featured evidence
35.3%DLP-114 Alpha-7 (12-months)
NCT04418466 · Phase 1/2 · registry result, not featured evidence
44%
NCT01786239 · Phase na · registry result, not featured evidence
Discontinued due to AEs
1.4%180 mg subcutaneousa
NCT03978832 · Phase 4 · registry result, not featured evidence
show 22 more results
—CT - Oral Ris
NCT00333177 · Phase 4 · registry result, not featured evidence
—CT - RLAI
NCT00333177 · Phase 4 · registry result, not featured evidence
—HBT - Oral Ris
NCT00333177 · Phase 4 · registry result, not featured evidence
—HBT - RLAI
NCT00333177 · Phase 4 · registry result, not featured evidence
—
NCT01050582 · Phase 4 · registry result, not featured evidence
1.3%
NCT01855074 · Phase 4 · registry result, not featured evidence
0%
NCT00299702 · Phase 4 · registry result, not featured evidence
—PALI ER Delayed Initiation
NCT00535132 · Phase 4 · registry result, not featured evidence
—PALI ER Immediate Initiation
NCT00535132 · Phase 4 · registry result, not featured evidence
—
NCT00056498 · Phase 4 · registry result, not featured evidence
1.7%120 mg
NCT02109562 · Phase 3 · registry result, not featured evidence
0%90 mg
NCT02109562 · Phase 3 · registry result, not featured evidence
—4 mg
NCT04567524 · Phase 2 · registry result, not featured evidence
0%4 mg
NCT04567524 · Phase 2 · registry result, not featured evidence
—2 mg
NCT04567524 · Phase 2 · registry result, not featured evidence
0%2 mg
NCT04567524 · Phase 2 · registry result, not featured evidence
—120 mg
NCT01677377 · Phase 2 · registry result, not featured evidence
—90 mg
NCT01677377 · Phase 2 · registry result, not featured evidence
—60 mg
NCT01677377 · Phase 2 · registry result, not featured evidence
—DLP-114 Alpha-4 (6-months)
NCT04418466 · Phase 1/2 · registry result, not featured evidence
—DLP-114 Alpha-7 (12-months)
NCT04418466 · Phase 1/2 · registry result, not featured evidence
—
NCT01786239 · Phase na · registry result, not featured evidence
Serious AEs
4.3%180 mg subcutaneousa
NCT03978832 · Phase 4 · registry result, not featured evidence
show 22 more results
18.8%CT - Oral Ris
NCT00333177 · Phase 4 · registry result, not featured evidence
8.3%CT - RLAI
NCT00333177 · Phase 4 · registry result, not featured evidence
8.3%HBT - Oral Ris
NCT00333177 · Phase 4 · registry result, not featured evidence
0%HBT - RLAI
NCT00333177 · Phase 4 · registry result, not featured evidence
0%
NCT01050582 · Phase 4 · registry result, not featured evidence
1.3%
NCT01855074 · Phase 4 · registry result, not featured evidence
17.3%
NCT00299702 · Phase 4 · registry result, not featured evidence
4%PALI ER Delayed Initiation
NCT00535132 · Phase 4 · registry result, not featured evidence
3.1%PALI ER Immediate Initiation
NCT00535132 · Phase 4 · registry result, not featured evidence
3.3%
NCT00056498 · Phase 4 · registry result, not featured evidence
0.9%120 mg
NCT02109562 · Phase 3 · registry result, not featured evidence
0%90 mg
NCT02109562 · Phase 3 · registry result, not featured evidence
0%4 mg
NCT04567524 · Phase 2 · registry result, not featured evidence
—4 mg
NCT04567524 · Phase 2 · registry result, not featured evidence
0%2 mg
NCT04567524 · Phase 2 · registry result, not featured evidence
—2 mg
NCT04567524 · Phase 2 · registry result, not featured evidence
6.7%120 mg
NCT01677377 · Phase 2 · registry result, not featured evidence
0%90 mg
NCT01677377 · Phase 2 · registry result, not featured evidence
0%60 mg
NCT01677377 · Phase 2 · registry result, not featured evidence
0%DLP-114 Alpha-4 (6-months)
NCT04418466 · Phase 1/2 · registry result, not featured evidence
7.1%DLP-114 Alpha-7 (12-months)
NCT04418466 · Phase 1/2 · registry result, not featured evidence
0%
NCT01786239 · Phase na · registry result, not featured evidence
Most frequent reported AEs
180 mg subcutaneousa
upper respiratory tract infection 13%
blood prolactin increased 8.7%
decreased appetite 8.7%
NCT03978832 · Phase 4 · registry result, not featured evidence
show 18 more results
bmi increase normal/overweight to obese 31.3%
ldl or triglyceride increase 25%
prolactin related symptom 12.5%
NCT00333177 · Phase 4 · registry result, not featured evidence
bmi increase normal/overweight to obese 25%
prolactin related symptom 16.7%
ldl or triglyceride increase 8.3%
NCT00333177 · Phase 4 · registry result, not featured evidence
ldl or triglyceride increase 41.7%
prolactin related symptom 16.7%
bmi increase normal/overweight to obese 0%
NCT00333177 · Phase 4 · registry result, not featured evidence
bmi increase normal/overweight to obese 12.5%
ldl or triglyceride increase 6.3%
prolactin related symptom 6.3%
NCT00333177 · Phase 4 · registry result, not featured evidence
blood prolactin increased 0.8%
drug ineffective 0.8%
eye infection 0.8%
NCT01050582 · Phase 4 · registry result, not featured evidence
extrapyramidal disorder 1.3%
NCT01855074 · Phase 4 · registry result, not featured evidence
insomnia 26.3%
tremor 21.8%
anxiety 17.9%
NCT00299702 · Phase 4 · registry result, not featured evidence
constipation 9.1%
insomnia 9.1%
somnolence 8.1%
NCT00535132 · Phase 4 · registry result, not featured evidence
insomnia 9.2%
headache 8.2%
constipation 6.1%
NCT00535132 · Phase 4 · registry result, not featured evidence
120 mg
injection site pain 22.2% (placebo 19.5%)
headache 15.4% (placebo 23.7%)
weight increased 12.8% (placebo 3.4%)
NCT02109562 · Phase 3 · registry result, not featured evidence
90 mg
headache 17.4% (placebo 23.7%)
injection site pain 15.7% (placebo 19.5%)
weight increased 13% (placebo 3.4%)
NCT02109562 · Phase 3 · registry result, not featured evidence
4 mg
akathisia 25%
diarrhoea 25%
abdominal discomfort 0%
NCT04567524 · Phase 2 · registry result, not featured evidence
2 mg
alanine aminotransferase increased 25%
weight increased 25%
abdominal discomfort 0%
NCT04567524 · Phase 2 · registry result, not featured evidence
120 mg
cough 20%
dyspepsia 20%
weight increased 20%
NCT01677377 · Phase 2 · registry result, not featured evidence
90 mg
weight increased 33.3%
headache 20%
dyspepsia 13.3%
NCT01677377 · Phase 2 · registry result, not featured evidence
60 mg
weight increased 26.7%
headache 20%
rash 20%
NCT01677377 · Phase 2 · registry result, not featured evidence
arthralgia 21.4%
weight increased 21.4%
abdominal pain 14.3%
NCT04418466 · Phase 1/2 · registry result, not featured evidence
insomnia 21.4%
implant site pain 14.3%
injection site discomfort 14.3%
NCT04418466 · Phase 1/2 · registry result, not featured evidence

Notes

  1. aPopulation comparability has not been reviewed for these studies.

Reported by one asset only

Endpoints only one of the selected assets measured, so there is nothing to compare them against.

Risperidone (Risperdal)

PANSS Total -0.2 score @ 0wk180 mg subcutaneous
absolute change · score
No placebo or comparator arm
Total score change from baseline: Dose 1 Day 2
NCT03978832 · Phase 4 · registry result, not featured evidence
PANSS Total 0.9 score @ 1wk180 mg subcutaneous
absolute change · score
No placebo or comparator arm
Total score change from baseline: Dose 1 Day 8
NCT03978832 · Phase 4 · registry result, not featured evidence
PANSS Total 0.7 score @ 2wk180 mg subcutaneous
absolute change · score
No placebo or comparator arm
Total score change from baseline: Dose 1 Day 15
NCT03978832 · Phase 4 · registry result, not featured evidence
PANSS Total -0.4 score @ 3wk180 mg subcutaneous
absolute change · score
No placebo or comparator arm
Total score change from baseline: Dose 1 Day 22
NCT03978832 · Phase 4 · registry result, not featured evidence
PANSS Total -0.9 score @ 4wk180 mg subcutaneous
absolute change · score
No placebo or comparator arm
Total score change from baseline: Dose 2 Day 29
NCT03978832 · Phase 4 · registry result, not featured evidence
PANSS Total -0.5 score @ 7wk180 mg subcutaneous
absolute change · score
No placebo or comparator arm
Total score change from baseline: Dose 2 Day 50
NCT03978832 · Phase 4 · registry result, not featured evidence
PANSS Total -2.9 score @ 8wk180 mg subcutaneous
absolute change · score
No placebo or comparator arm
Total score change from baseline: Dose 3 Day 57
NCT03978832 · Phase 4 · registry result, not featured evidence
PANSS Total -0.9 score @ 12wk180 mg subcutaneous
absolute change · score
No placebo or comparator arm
Total score change from baseline: Dose 4 Day 85
NCT03978832 · Phase 4 · registry result, not featured evidence
PANSS Total 1.6 score @ 16wk180 mg subcutaneous
absolute change · score
No placebo or comparator arm
Total score change from baseline: Day 113-EOS
NCT03978832 · Phase 4 · registry result, not featured evidence
CGI-S -0.1 score @ 0wk180 mg subcutaneous
absolute change · score
No placebo or comparator arm
Change from baseline: Dose 1/Day 2
NCT03978832 · Phase 4 · registry result, not featured evidence
CGI-S 0 score @ 1wk180 mg subcutaneous
absolute change · score
No placebo or comparator arm
Change from baseline: Dose 1/Day 8
NCT03978832 · Phase 4 · registry result, not featured evidence
CGI-S 0 score @ 2wk180 mg subcutaneous
absolute change · score
No placebo or comparator arm
Change from baseline: Dose 1/Day 15
NCT03978832 · Phase 4 · registry result, not featured evidence

+ 24 further endpoints in the CSV export.

Bipolar Disorder

Shared mechanism: Dopamine D2 and serotonin 5-HT2A receptors (antagonist) · full Bipolar Disorder pipeline

Milsaperidone (VHX-896)

Marketed by Vanda Pharmaceuticals

Approved in Bipolar Disordersmall molecule
Weak signal

NCT06494397 · Phase 1 · completed

Every participant in this trial received both VHX-896 and iloperidone, just in a different order, so there is no separate group that shows what happens without VHX-896, and nobody was blinded to which drug was being given at each stage. The trial measured drug levels in the blood to compare the two products, not any change in psychiatric symptoms, and results have not been posted yet.

No aligned efficacy figure on record for this race.

Risperidone (Risperdal)

Marketed by Johnson & Johnson

Approved in Bipolar Disordersmall molecule
not yet graded

No graded featured trial for this indication yet; the grade above reflects that absence, not a judgment.

Next expected readout: June 2028 · NCT07665073 (registry estimate)

No aligned efficacy figure on record for this race.

Results for Bipolar Disorder

There are not yet structured results for two selected drugs in this indication. Available results are listed below instead of an empty comparison table.

Milsaperidone (VHX-896): no structured comparison results are available for Bipolar Disorder.

Available safety results

Risperidone (Risperdal)

Dropout rate
0%
NCT01050582 · Phase 4 · registry result, not featured evidence
Discontinued due to AEs
—
NCT01050582 · Phase 4 · registry result, not featured evidence
Serious AEs
0%
NCT01050582 · Phase 4 · registry result, not featured evidence
Most frequent reported AEs
blood prolactin increased 0.8%
drug ineffective 0.8%
eye infection 0.8%
NCT01050582 · Phase 4 · registry result, not featured evidence

The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Milsaperidone (VHX-896)'s landscape · Risperidone (Risperdal)'s landscape